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1 
METHODS OF ADMINISTERING IGGl 
ANTIBODIES AND METHODS OF 
SUPPRESSING ANGIOGENESIS 
2 
A commonly-used anti-angiogenic drug is bevacizumab, 
a humanized IgG 1 monoclonal antibody that targets vascular 
endothelial growth factor-A (VEGFA, a.k.a. VEGF) and is 
approved for various cancers and widely used in age-related 
RELATED APPLICATION 
This application claims priority from U.S. Provisional 
Patent Application Ser. No. 61/780,105, which was filed on 
Mar. 13, 2013, the entire disclosure of which is incorporated 
herein by this reference. 
5 macular degeneration. Bevacizumab had been thought to 
inhibit angiogenesis by targeting human VEGFA; however, 
it was reported to inhibit angiogenesis in mouse models8 - 14, 
even though bevacizumab does not target mouse VEGFA 
and is specific for human VEGFA. 
10 The present inventor surprisingly discovered that bevaci-
TECHNICAL FIELD 
zumab acts to suppress angiogenesis not only via its target, 
VEGFA, but rather also via activation of Fey RI via its Fe 
fragment (FcyRI is also known as CD64). The present 
inventor surprisingly discovered that bevacizumab's anti-The presently-disclosed subject matter relates to admin-
istration of IgG 1 antibodies, and to suppression of angio-
genesis using intravenous human immunoglobulin (IVIG), 
IgGl antibodies, and/or Fe fragments of same. 
15 angiogenic activity occurs not only because it is designed to 
target a particular protein, but also because it includes an Fe 
fragment that is capable of activating Fey RI. 
INTRODUCTION 
In this regard, as disclosed herein, any IgG 1 antibody 
including an Fe fragment, intravenous human immuno-
20 globulin (IVIG), and/or isolated Fe fragment can be used to 
Angiogenesis is a process of forming new capillaries as 
endothelial cells of preexisting blood vessels decompose 
extracellular matrix, migrate, divide, and differentiate to 
form new capillaries, which does not occur except in a 
particular case, such as growth, reproduction, or healing 25 
wounds. However, excessive angiogenesis has been reported 
suppress angiogenesis. 
Several monoclonal antibody therapies are now approved 
by the FDA, EMEA, and other regulatory agencies for the 
treatment of numerous diseases including age-related macu-
lar degeneration (AMD), asthma, autoimmune disorders, 
and various cancers 1 . In addition, there are hundreds of 
monoclonal antibodies under evaluation in thousands of 
clinical trials. Such antibodies that were not contemplated 
for use to suppress angiogenesis are proposed herein for a 
in diseases such as growth and metastasis of a malignant 
tumor, age-related macular degeneration, rheumatoid arthri-
tis, diabetic retinopathy, psoriasis, and chronic inflamma-
tion. 30 unique use, with the benefit that many of such antibodies 
have already obtained regulatory approval and/or are under-
going clinical safety assessment. 
Formation of blood vessels requires a complicate set of 
processes including growth, migration, and division of vas-
cular endothelial cells, and formation of capillaries, and 
many vascular endothelial growth factors and vascular 
endothelial inhibition factors involved in the set of processes 35 
have been discovered. The vascular endothelial inhibition 
factors are activated against activity of the vascular endothe-
lial growth factors, which are necessary in the formation of 
blood vessel. Therefore, many anti-angiogenesis products 
target vascular endothelial growth factor-A (VEGFA, a.k.a. 40 
VEGF). Fewer products act to suppress angiogenesis via 
other targets. 
Aberrant angiogenesis is implicated in a variety of dis-
eases that collectively affect nearly 10% of the world's 
population. Accordingly, there remains a need in the art for 45 
unique angiogenesis suppressors and new approaches for 
suppressing angiogenesis to facilitate the treatment of such 
diseases. 
The presently-disclosed subject matter includes methods 
of suppressing angiogenesis, which involve administering to 
a subject in need of suppression of angiogenesis an isolated 
Fe fragment of an IgG 1 antibody, an IgG 1 antibody, and/or 
WIG. 
In some instances, IgG 1 antibodies can be administered to 
treat a subject wherein suppression of angiogenesis is con-
traindicated (including wherein suppression of angiogenesis 
is not desired). In this regard, the presently-disclosed subject 
matter also provides for methods of administering IgG 
antibodies if suppression of angiogenesis in the subject is 
not contraindicated. 
The present inventor has also surprisingly discovered that 
intravitreous administration of Fe fragment-containing IVIG 
suppressed choroidal neovascularization as effectively as 
intravenous administration. Accordingly, the presently-dis-
closed subject matter further includes methods of suppress-
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
50 ing angiogenesis, including intravitreously administering to 
the subject an isolated Fe fragment of an IgG 1 antibody, an 
IgGl antibody, and/or IVIG. Screening methods for identi-
fying angiogenesis suppressors are also provided herein. 
55 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea- 60 
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 65 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the invention are set forth with 
particularity in the appended claims. A better understanding 
of the features and advantages of the present invention will 
be obtained by reference to the following detailed descrip-
tion that sets forth illustrative embodiments, in which the 
principles of the invention are used, and the accompanying 
drawings of which: 
FIG. 1: Avastin does not inhibit mouse VEGF signaling. 
Western blotting shows that mouse VEGF (mVegf) and 
human VEGF (hVegf) induce phosphorylation ofVEGFR2 
(pVegfr2) in mouse Py4 endothelial cells. A neutralizing 
US 10,562,974 B2 
3 
anti-mouse Vegf antibody reduced mouse VEGF induced 
VEGF2 phosphorylation but Avastin (a humanized IgGl 
antibody that specifically targets human Vegfbut not mouse 
Vegf) did not do so. Avastin did reduce human VEGF 
induced VEGFR2 phosphorylation. Tubulin blotting shows 5 
protein loading. 
FIG. 2: Lucentis does not inhibit corneal neovasculariza-
tion. Avastin (a full length humanized IgGl antibody that 
specifically targets human VEGF-A but not mouse Vegfa; 
red), but not Lucentis (a humanized IgGl Fab antibody 10 
fragment that specifically targets human VEGF-A but not 
mouse Vegfa; gray), reduced corneal hemangiogenesis com-
pared to PBS (black) injection in wild-type mice. * P<0.05. 
FIG. 3: Avastin and human IgGl inhibit mouse corneal 
neovascularization. Intrastromal injection of Avastin 15 
reduced corneal hemangiogenesis compared to PBS injec-
tion in wild-type mice. Human IgGl (higG) from R&D 
Systems also reduced corneal hemangiogenesis compared to 
PBS. * P<0.05. 
4 
FIG. 15: Coadministration of a peptide inhibitor of IgG 
binding to FcyRI (PAM), compared to a control peptide 
(CP), blocked the inhibition of hind limb ischemia-induced 
neovascularization by Avastin in wild-type mice. 
FIG. 16: Campath inhibits corneal neovascularization. 
Intrastromal injection ofCampath (a humanized IgGl anti-
body that specifically targets human CD52 but not mouse 
CD52; red) reduced corneal hemangiogenesis compared to 
PBS (black) injection in wild-type mice. 
FIG. 17: Humira inhibits corneal neovascularization. 
Intrastromal injection of Humira (a humanized IgGl anti-
body that specifically targets human TNF-a but not mouse 
TNF-a) reduced corneal hemangiogenesis compared to PBS 
injection in wild-type mice. 
FIG. 18: Actemra inhibits corneal neovascularization. 
Intrastromal injection of Actemra (a humanized IgGl anti-
body that specifically targets human IL-6R but not mouse 
IL-6R) reduced corneal hemangiogenesis compared to PBS 
FIG. 4: Fe fragment of human IgGl inhibits corneal 
neovascularization. The Fe fragment of human IgGl 
reduced corneal hemangiogenesis compared to PBS injec-
tion in wild-type mice. 
20 injection in wild-type mice. * P<0.05. 
FIG. 19: Arzerra and Synagis inhibit corneal neovascu-
larization. Intrastromal injection of Arzerra (a humanized 
IgG 1 antibody that specifically targets human CD20 but not 
mouse CD20) or of Synagis (a humanized IgGl antibody FIG. 5: Fe fragment of Avastin inhibits corneal neovas-
cularization. An enzymatically cleaved Fe fragment of Avas-
tin (red) reduced corneal hemangiogenesis compared to PBS 
(black) injection in wild-type mice. 
25 that specifically targets the F protein of respiratory syncytial 
virus) reduced corneal hemangiogenesis compared to PBS 
injection in wild-type mice. * P<0.05. 
FIG. 20: Xolair inhibits corneal neovascularization. FIG. 6: Fab fragment of Avastin does not inhibit corneal 
neovascularization. An enzymatically cleaved Fab fragment 
of Avastin did not reduce corneal hemangiogenesis com-
pared to PBS injection in wild-type mice. 
Intrastromal injection ofXolair ( a humanized IgG 1 antibody 
30 that specifically targets human IgE but not mouse IgE) 
reduced corneal hemangiogenesis compared to PBS injec-
tion in wild-type mice. * P<0.05. FIG. 7: Deglycosylated Avastin does not inhibit corneal 
neovascularization. A deglycosylated form of Avastin, 
which does not bind Fey RI, did not reduce corneal heman-
giogenesis compared to PBS injection in wild-type mice. 35 
NS, not significant. 
FIG. 8: Avastin does not inhibit corneal neovasculariza-
tion in Fcgrl -/- mice. Avastin did not reduce corneal heman-
giogenesis compared to PBS injection in Fcgr1-1- mice. 
FIG. 9: Avastin and human IgGl inhibit choroidal neo- 40 
vascularization. Intravitreous injection of Bevacizumab 
(Avastin) or human IgGl reduced laser-induced choroidal 
neovascularization in wild-type mice compared to PBS. * 
P<0.05 compared to PBS. 
FIG. 10: Lucentis does not inhibit choroidal neovascular- 45 
ization. Intravitreous injection of Ranibizumab (Lucentis) 
did not reduce laser-induced choroidal neovascularization in 
wild-type mice compared to PBS. No significant difference. 
FIG. 11: Intravitreous injection of Avastin or human IgG 1 
did not reduce laser-induced choroidal neovascularization in 50 
Fcgr1-1- mice compared to PBS. No significant difference. 
FIG. 21: Arzerra inhibits choroidal neovascularization. 
Intravitreous injection of atumumab (Arzerra) reduced laser-
induced choroidal neovascularization in wild-type mice 
compared to PBS. * P<0.05 compared to PBS. 
FIG. 22: Synagis inhibits choroidal neovascularization. 
Intravitreous injection of palivizumab (Synagis), an anti-
respiratory syncitial virus protein F IgG 1 antibody that does 
not target any mouse protein, reduced laser-induced chor-
oidal neovascularization in wild-type mice compared to 
PBS. * P<0.05 compared to PBS. 
FIG. 23: Xolair inhibits choroidal neovascularization. 
Intravitreous injection of omalizumab (Xolair), an anti-
human IgE IgG 1 antibody that does not bind mouse IgE, 
reduced laser-induced choroidal neovascularization in wild-
type mice compared to PBS. * P<0.05 compared to PBS. 
FIG. 24: Actemra inhibits choroidal neovascularization. 
Intravitreous injection of tocilizumab (Actemra), an anti-
human IL-6R IgG 1 antibody that does not bind mouse 
IL-6R, reduced laser-induced choroidal neovascularization 
in wild-type mice compared to PBS. * P<0.05 compared to 
PBS. 
FIG. 25: Campath inhibits choroidal neovascularization. 
FIG. 12: Coadministration of a peptide inhibitor of IgG 
binding to FcyRI (PAM), compared to a control peptide 
(CP), blocked the inhibition oflaser-induced choroidal neo-
vascularization by Avastin in wild-type mice. 
FIG. 13: (A) Color laser doppler studies were performed 
55 Intravitreous injection (25 µg) of alemtuzumab (Campath), 
an anti-human CD52 IgGl antibody that does not bind 
mouse CD52, reduced laser-induced choroidal neovascular-
ization in wild-type mice compared to PBS. * P<0.05 
at 2 and 7 days after femoral artery ligation (NI, nonisch-
emic; I, ischemic). The blue areas denote low flow/ischemic 
regions, whereas red denotes normal perfusion. Represen-
tative images show that whereas animals treated with intra- 60 
muscular PBS demonstrate substantial reperfusion of the 
limb at 7 days, those treated with Avastin or human IgG 
injections did not. 
FIG. 14: Intramuscular administration of Avastin and 
human IgG but not Lucentis in wild-type mice reduced 65 
blood capillary density, expressed as % vascularized area 
normalized to myocyte numbers, compared to PBS. 
compared to PBS. 
FIG. 26: Humira inhibits choroidal neovascularization. 
Intravitreous injection (25 µg) of adalimumab (Humira), an 
anti-human TNFa IgGl antibody that does not bind mouse 
TNFa, reduced laser-induced choroidal neovascularization 
in wild-type mice compared to PBS. * P<0.05 compared to 
PBS. 
FIG. 27: IVIG inhibits corneal neovascularization. Intra-
venous administration of intravenous human immunoglobu-
US 10,562,974 B2 
5 
!in (WIG) reduced corneal hemangiogenesis compared to 
intravenous PBS (IVPBS) injection in wild-type mice. * 
P<0.05. 
FIG. 28: IVIG inhibits choroidal neovascularization. 
6 
FIG. 40: c-cbl is required for Avastin to inhibit corneal 
neovascularization. Avastin did not reduce corneal heman-
giogenesis compared to PBS injection in c-cb1-1- mice. No 
significant difference. 
Intravenous administration of intravenous human immuno- 5 
globulin (Ivig) reduced the volume of laser-induced chor-
oidal neovascularization in wild-type mice. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
FIG. 29: IVIG inhibits hind limb neovascularization. 
Intravenous administration of intravenous human immuno-
globulin (Ivig) reduced hind limb-induced neovasculariza-
tion in wild-type mice. 
FIG. 30: Local IVIG inhibits choroidal neovasculariza-
tion. Intravitreous injection of human "intravenous" immu-
noglobulin reduced laser-induced choroidal neovasculariza-
tion in wild-type mice compared to PBS. * P<0.05 compared 
to PBS. 
FIG. 31: Avastin inhibits corneal neovascularization in 
The details of one or more embodiments of the presently-
10 disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
15 and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
humanized FcyR mice. Intravenous administration of intra-
venous human immunoglobulin (IVIG) reduced corneal 20 
hemangiogenesis compared to intravenous PBS (IVPBS) 
injection in humanized FcyR mice compared to PBS. * 
P<0.05 compared to PBS. 
this document, including definitions, will control. 
The presently-disclosed subject matter includes methods 
of administering an IVIG containing an Fe fragment, an 
IgG 1 antibody contacting an Fe fragment, and/or an isolated 
Fe fragment. The presently-disclosed subject matter further 
includes methods of suppressing angiogenesis. The pres-FIG. 32: Avastin inhibits choroidal neovascularization in 
humanized FcyR mice. Intravitreous injection of Avastin 
reduced laser-induced choroidal neovascularization in 
humanized FcyR mice compared to PBS. * P<0.05 com-
pared to PBS. 
FIG. 33: FcyRl expression on resident cells is not 
required for Avastin to inhibit corneal neovascularization. 
Avastin reduced corneal hemangiogenesis compared to PBS 
injection in Fcgrl -/- mice that had been irradiated and had 
their bone marrow reconstituted with wild-type mouse bone 
marrow. * P<0.05. 
FIG. 34: FcyRl expression on circulating cells is required 
for Avastin to inhibit corneal neovascularization. Avastin did 
not reduce corneal hemangiogenesis compared to PBS injec-
tion in wild-type mice that had been irradiated and had their 
bone marrow reconstituted with Fcgrl -/- mouse bone mar-
row. No significant difference. 
FIG. 35: FcyRl expression on circulating cells, but not on 
resident cells, is required for Avastin to inhibit choroidal 
neovascularization. Intravitreous administration of Avastin 
reduced laser-induced choroidal neovascularization com-
pared to PBS injection in Fcgr1-1- mice that had been 
irradiated and had their bone marrow reconstituted with 
wild-type mouse bone marrow. Avastin did not reduce 
laser-induced choroidal neovascularization compared to 
PBS injection in wild-type mice that had been irradiated and 
had their bone marrow reconstituted with Fcgrl -/- mouse 
bone marrow. 
FIG. 36: Avastin and IgG inhibit mouse Vegfa-induced 
migration of wild-type (wt) mouse bone marrow derived 
macrophages across a Transwell filter. 
FIG. 37: Avastin and IgG do not inhibit mouse Vegfa-
induced migration of Fcgrl knockout (ko) mouse bone 
marrow derived macrophages across a Transwell filter. 
25 ently-disclosed subject matter further includes methods of 
screening for angiogenesis suppressors. 
With regard to the use of an isolated Fe fragment, it is 
noted that Fcgrl has not been previously associated with 
suppression of angiogenesis in any published report. More-
30 over, since both Lucentis (an IgGl Fab fragment) and 
Avastin (a full-length IgGl containing both the Fab and Fe 
fragments) suppress angiogenesis, one of ordinary skill in 
the art would have surmised that the Fe fragment is unnec-
essary for anti-angiogenic activity. As such, it is unexpected 
35 that the isolated Fe fragment has utility for anti-angiogenic 
treatment. 
Unless otherwise indicated, the term "administering" is 
inclusive of all means known to those of ordinary skill in the 
art for providing a pharmaceutical preparation to a subject, 
40 administration by inhalation, nasal administration, topical 
administration, intravaginal administration, ophthalmic 
administration, intraaural administration, intracerebral 
administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste-
45 rior juxtascleral administration, subretinal administration, 
suprachoroidal administration, cell-based administration or 
production, rectal administration, and parenteral administra-
tion, including injectable such as intravenous administra-
tion, intra-arterial administration, intramuscular administra-
50 tion, and subcutaneous administration. Administration can 
be continuous or intermittent. A preparation can be admin-
istered therapeutically; that is, administered to treat an 
existing condition of interest. A preparation can be admin-
istered prophylactically; that is, administered for prevention 
55 of a condition of interest. 
FIG. 38: Avastin and IgG do not inhibit mouse Vegfa- 60 
induced migration of c-cbl knockout (ko) mouse bone 
marrow derived macrophages across a Transwell filter. 
As used herein, the term "contraindicated" refers to any 
condition in a patient which renders a particular line of 
treatment, including the administration of drugs (e.g., an 
anti-angiogenic agent), undesirable or improper. This con-
dition may be preexisting, or may develop while the patient 
is taking the drugs, including conditions which may result 
directly or indirectly from treatment with the drugs. A 
particular line of treatment, including administration of 
drugs, may also be considered "contraindicated," as the term 
is used herein, if use of a drug by subjects who are also 
taking another drug is known or suspected of producing an 
adverse side effect in those subjects. 
FIG. 39: Stimulation with Avastin (100 µg/ml) induced 
phosphorylation of c-cbl (p-c-cbl) in wild-type mouse bone 
marrow derived macrophages over a 20-minute period com- 65 
pared to no treatment (NoTx), as monitored by western 
blotting. 
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As used herein, "IgG 1 antibody" or "IgG 1" refer to 
immunoglobulin G subclass 1, including an Fe region or Fe 
fragment, i.e., the Fe fragment has not been cleaved from the 
antibody. Antibodies as used herein include monoclonal, 
polyclonal, chimeric, single chain, bispecific, simianized, 5 
human, and humanized or primatized antibodies. As used 
herein, "intravenous human immunoglobulin (IVIG)" refers 
to the blood product, including IgG, including an Fe region 
or Fe fragment, i.e., the Fe fragment has not been cleaved 
from the antibody. "Fe region" and "Fe fragment" refer to 10 
the Fragment, crystalizable (Fe) region of an IgG 1 antibody. 
The term "isolated" when used in the context of an Fe 
fragment, is the Fe fragment that exists apart from the 
remainder of an IgGl antibody. Use of the term "isolated" 
in connection with an Fe fragment does not preclude that the 15 
Fe fragment may comprise additional amino acids or other 
elements that are not particularly part of the Fe region; 
rather, it is simply to clarify that the Fe fragment exists apart 
from the remainder of the IgG 1 antibody. 
As used herein, the term "subject" refers to a target of 20 
treatment. The subject of the herein disclosed methods can 
be a vertebrate, such as a mammal, a fish, a bird, a reptile, 
or an amphibian. Thus, the subject of the herein disclosed 
methods can be a human or nonhuman. Thus, veterinary 
therapeutic uses are provided in accordance with the pres- 25 
ently disclosed subject matter. 
As will be recognized by one of ordinary skill in the art, 
the terms "suppression," "suppressing," "suppressor," "inhi-
bition," "inhibiting" or "inhibitor" do not refer to a complete 
elimination of angiogenesis in all cases. Rather, the skilled 30 
artisan will understand that the term "suppressing" or 
"inhibiting" refers to a reduction or decrease in angiogen-
esis. Such reduction or decrease can be determined relative 
8 
IgG 1 antibody. In some embodiments, the IgG 1 antibody is 
not selected from the IgG 1 antibodies set forth in Table A. 
In some embodiments, the IgG 1 antibody is selected from 
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In some embodiments of the presently-disclosed subject 
matter the method includes identifying a subject in need of 
suppression of angiogenesis; and intravitreously administer-
ing to the subject an isolated Fe fragment of an IgGl 
antibody, an IgG 1 antibody, and/or intravenous human to a control. In some embodiments, the reduction or decrease 
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26,27, 28,29,30, 31, 32,33,34, 35,36,37,38, 39,40,41, 
42,43, 44,45,46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease. 
35 immunoglobulin (IVIG). 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 
symptoms associated with the condition of interest. 
In some embodiments of the presently-disclosed subject 
matter the method includes identifying a subject in need of 
treatment with an IgG 1 antibody; determining whether sup-
pression of angiogenesis in the subject is contraindicated; 
and if suppression of angiogenesis in the subject is not 
contraindicated, administering the IgG 1 antibody. In some 
embodiments, the IgG 1 antibody is not selected from the 
IgG 1 antibodies set forth in Table A. In some embodiments, 
the IgG 1 antibody is selected from the IgG 1 antibodies set 
forth in Table B. 
In some embodiments of the presently-disclosed subject 
matter the method includes identifying a subject in need of 
suppression of angiogenesis; and administering to the sub-
ject an isolated Fe fragment of an IgGl antibody and/or an 
Neither WIG nor IgGl antibodies (apart fromAvastin) are 
formulated for intraocular administration. As such, they are 
not contemplated for such a mode of delivery. Furthermore, 
the IgG 1 the IgG 1 antibodies in Table B are not known to 
40 influence previously described pathways of angiogenesis. As 
such, their use in the eye would not be expected. Neverthe-
less, the present inventor discovered that Intravitreous 
administration is surprisingly effective. 
Damianovich et al. reports that WIG reduces angiogenesis 
45 and attributes it to the presence of anti-VEGF antibodies 
contained in the IVIG. Therefore, one of ordinary skill in the 
art would not expect "generic" IgGs not containing anti-
VEGF antibodies to suppress angiogenesis. See Dami-
anovich et al. Anti-vascular endothelial growth factor 
50 (VEGF) specific activity of intravenous immunoglobulin 
(IVIg). Int. Immunol. (2009) 21 (9): 1057-1063. Surpris-
ingly, as reported herein, such IgGs that do not contain 
anti-VEGF antibodies indeed suppress angiogenesis. 
The presently-disclosed subject matter includes methods 
55 involving administration of a combination of an isolated Fe 
fragment of an IgGl antibody, an IgGl antibody, and/or 
IVIG; and a drug that is otherwise useful for in the context 
of suppressing angiogenesis. The presently-disclosed sub-
ject matter further includes compositions that include an 
60 isolated Fe fragment of an IgG 1 antibody, an IgG 1 antibody, 
and/or IVIG; and a drug that is otherwise useful for in the 
context of suppressing angiogenesis. 
In some embodiments of the methods as described herein, 
the method further involves administering a drug selected 
65 from the group consisting of: Avastin, Lucentis, Herceptin, 
sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votri-
ent), everolimus (Afinitor). 
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In some embodiments of the presently-disclosed subject 
matter, a method of suppressing angiogenesis involves iden-
tifying a subject in need of suppression of angiogenesis; and 
administering to the subject an isolated Fe fragment of an 
IgGl antibody, an IgGl antibody, and/or IVIG; and a drug 5 
selected from the group consisting of: Avastin, Lucentis, 
Herceptin, sorafenib (Nexavar), sunitinib (Sutent), 
pazopanib (Votrient), everolimus (Afinitor). 
In some embodiments of the presently-disclosed subject 
matter, a method of suppressing angiogenesis involves iden- 10 
tifying a subject in need of suppression of angiogenesis; and 
administering to the subject a pharmaceutical composition, 
which includes an isolated Fe fragment of an IgG 1 antibody, 
an IgG 1 antibody, and/or IVIG; and a drug selected from the 
group consisting of: Avastin, Lucentis, Herceptin, sorafenib 15 
(Nexavar), sunitinib (Sutent), pazopanib (Votrient), everoli-
mus (Afinitor). 
The presently-disclosed subject matter further includes a 
pharmaceutical composition, comprising an isolated Fe frag-
ment of an IgGl antibody, an IgGl antibody, and/or IVIG; 20 
and a drug selected from the group consisting of: Avastin, 
Lucentis, Herceptin, sorafenib (Nexavar), sunitinib (Sutent), 
pazopanib (Votrient), everolimus (Afinitor). 
In some embodiments, the composition can further 
include a pharmaceutically acceptable carrier. As used 25 
herein, the term "pharmaceutically acceptable carrier" refers 
to sterile aqueous or nonaqueous solutions, dispersions, 
suspensions or emulsions, as well as sterile powders for 
reconstitution into sterile injectable solutions or dispersions 
just prior to use. Examples of suitable aqueous and non- 30 
aqueous carriers, diluents, solvents or vehicles include 
water, ethanol, polyols (such as glycerol, propylene glycol, 
polyethylene glycol and the like), carboxymethylcellulose 
and suitable mixtures thereof, vegetable oils (such as olive 
oil) and injectable organic esters such as ethyl oleate. Proper 35 
fluidity can be maintained, for example, by the use of 
coating materials such as lecithin, by the maintenance of the 
required particle size in the case of dispersions and by the 
use of surfactants. These compositions can also contain 
adjuvants such as preservatives, wetting agents, emulsifying 40 
agents and dispersing agents. Prevention of the action of 
microorganisms can be ensured by the inclusion of various 
antibacterial and antifungal agents such as paraben, chlo-
robutanol, phenol, sorbic acid and the like. It can also be 
desirable to include isotonic agents such as sugars, sodium 45 
chloride and the like. Prolonged absorption of the injectable 
pharmaceutical form can be brought about by the inclusion 
of agents, such as aluminum monostearate and gelatin, 
which delay absorption. Injectable depot forms are made by 
forming microencapsule matrices of the drug in biodegrad- 50 
able polymers such as polylactide-polyglycolide, poly(or-
thoesters) and poly(anhydrides). Depending upon the ratio 
of drug to polymer and the nature of the particular polymer 
employed, the rate of drug release can be controlled. Depot 
injectable formulations are also prepared by entrapping the 55 
drug in liposomes or microemulsions which are compatible 
with body tissues. The injectable formulations can be ster-
ilized, for example, by filtration through a bacterial-retaining 
filter or by incorporating sterilizing agents in the form of 
sterile solid compositions which can be dissolved or dis- 60 
persed in sterile water or other sterile injectable media just 
prior to use. Suitable inert carriers can include sugars such 
as lactose. Desirably, at least 95% by weight of the particles 
10 
with angiogenesis. Conditions associated with angiogenesis 
will be known to those of ordinary skill in the art and 
include, but are not limited to cancer, diabetic blindness, 
age-related macular degeneration, rheumatoid arthritis, pso-
riasis, atherosclerosis. 
The presently-disclosed subject matter further includes 
methods of identifying angiogenesis suppressors, including 
measuring activation of FcyRI and/or c-cbl. In some 
embodiments, the method of identifying angiogenesis sup-
pressors involves determining the ability of the candidate 
suppressor to induce phosphorylation of c-cbl in macro-
phages, endothelial cells, or other cells, e.g., by Western 
blotting. In some embodiments, the method of identifying 
angiogenesis suppressors involves determining the ability of 
the candidate suppressor to bind with Fey RI, e.g., by ELISA 
or surface plasmon resonance assays. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth herein to facilitate explanation of the presently-
disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
of the active ingredient have an effective particle size in the 
range of 0.01 to 10 micrometers. 
The presently-disclosed subject matter is further illus-
65 trated by the following specific but non-limiting examples. 
In some embodiments of the methods described herein, 
the subject in need of treatment for a condition associated 
The following examples may include compilations of data 
that are representative of data gathered at various times 
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during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
Example 1: Bevacizumab Inhibits Mouse Corneal 
Angiogenesis Via FcyRI 
12 
control peptide, eliminated the ability of bevacizumab to 
inhibit choroidal neovascularization in wild-type mice (FIG. 
12). 
Example 3: Bevacizumab Inhibits Mouse Hind 
Limb Angiogenesis Via FcyRI 
Next, an angiogenesis model outside the eye was tested; 
hind limb ischemia was induced by femoral artery ligation, 
Bevacizumab has no detectable binding to mouse Vegfa 
by surface plasmon resonance and does not block mouse 
Vegfa-induced retinal capillary endothelial cell prolifera-
tion5-7. To further verify that bevacizumab does not func-
tionally neutralize mouse Vegfa, its ability to inhibit the 
activation of the Vegfr2 receptor tyrosine kinase in mouse 
Py4 hemangioma endothelial cells was tested. As expected, 
bevacizumab inhibited Vegfr2 phosphorylation induced by 
human VEGFA but not by mouse Vegfa (FIG. 1). In contrast, 
10 
and drugs were administered intramuscularly at the time of 
surgery and 2 days thereafter. Color laser doppler imaging 2 
days after ligation revealed significant reduction in blood 
flow in the injured limbs of all experimental groups. By day 
7, PBS-injected limbs exhibited vascular rescue that was 
comparable to the contralateral untreated, nonischemic limb; 
an anti-mouse Vegfa neutralizing antibody blocked mouse 
Vegfa-induced Vegfr2 phosphorylation. 
15 however, limbs injected with bevacizumab or human IgGl 
exhibited suppressed revascularization and diminished per-
fusion (FIG. 13). There was a corresponding reduction in 
CD31 + capillary density (hemangiogenesis) in the bevaci-
zumab-treated and human IgG I-treated limbs compared 
The effects ofbevacizumab were tested in a mouse model 
20 with the PBS-treated group (FIG. 14). The peptide that 
blocks IgG binding to FcyRI eliminated the ability of 
bevacizumab to inhibit hind limb neovascularization in 
wild-type mice (FIG. 15). 
of suture-injury-induced corneal angiogenesis that is patho-
physiologically relevant to the human condition and is 
driven in large part by Vegfa16 . Various drugs were injected 
into the cornea stroma immediately after surgery and at 4 25 
and 8 days thereafter. By day 10, it was found that bevaci-
zumab inhibited corneal hemangiogenesis in wild-type mice 
compared to PBS administration (FIG. 2). However, admin-
istration of equimolar amounts of ranibizumab, a humanized 
monoclonal IgGl Fab fragment that binds human VEGFA 30 
but not mouse Vegfa6 •1 7, did not inhibit corneal hemangio-
genesis (FIG. 2). Since bevacizumab and ranibizumab had 
nonsynonymous effects in this mouse model, it was sus-
pected that the anti-angiogenic action of bevacizumab was 
due not to Vegfa inhibition but rather due to IgGl Fe- 35 
mediated effects. 
Example 4: Numerous Human IgG 1 s Inhibit Mouse 
Models of Angiogenesis Via Fey RI 
Next, several human or humanized IgGl monoclonal 
antibodies that are approved for treatment of various human 
diseases were tested-adalimumab (Humira™: anti-TNFa), 
alemtuzumab (Campath™: anti-CD52), ofatumumab 
(Arzerra™: anti-CD20), omalizumab (Xolair™: anti-IgE), 
tocilizumab (Actemra™: anti-IL-6R)-and that do not bind 
the mouse homologues of their intended human protein 
targets, as well as palivizumab (Synagis: anti-respiratory 
syncitial virus protein F), which has no mammalian target. 
It was found that these antibodies reduced both corneal and 
choroidal angiogenesis in wild-type mice (FIG. 16-26). 
Collectively, these data indicate that angioinhibition is a 
target-independent class effect of human or humanized IgG 1 
40 monoclonal antibodies that is mediated via FcyRI. 
Indeed, purified human IgG 1 as well as recombinant 
human IgGl-Fc reduced corneal hemangiogenesis in wild-
type mice (FIGS. 3 and 4). The Fab and Fe fragments of 
bevacizumab resulting from papain enzymatic digestion 
were tested and it was found that bevacizumab-Fc but not 
bevacizumab-Fab reduced corneal hemangiogenesis in wild-
type mice (FIGS. 5 and 6). Deglycosylation of human IgG 1 
dramatically reduces its binding to the high affinity FcyRI 
receptor (encoded by Fcgrl)18•19 . It was found that degly- 45 
cosylated bevacizumab did not reduce corneal hemangio-
genesis in wild-type mice (FIG. 7). In addition, bevaci-
zumab did not inhibit corneal hemangiogenesis in Fcgr1-1-
mice (FIG. 8). Collectively, these data indicate that bevaci-
zumab reduces mouse corneal neovascularization via FcyRI 50 
and not Vegfa inhibition. 
Example 2: Bevacizumab Inhibits Mouse Choroidal 
Angiogenesis Via FcyRI 
Example 5: IVIG Inhibit Mouse Models of 
Angiogenesis Via FcyRI 
Human intravenous immunoglobulin (WIG), a purified 
IgG fraction obtained from the pooled plasma of thousands 
of donors and comprised principally oflgG 1, is approved for 
the treatment of numerous primary immunodeficiency24 . It 
is also widely used in an "off-label" fashion to treat a wide 
range of dermatological, neurological, inflammatory, and 
transplantation-related diseases and widely used to treat 
inflammatory diseases. It was found that intravenous admin-
istration of IVIG inhibited corneal and choroidal neovascu-
larization in wild-type mice, compared to PBS administra-
tion (FIG. 27-29). The degree of angioinhibition was similar 
Next, a mouse model of laser injury-induced choroidal 
neovascularization was tested, which is a widely used model 
55 to that exerted by intraocular administration of various 
humanized IgG 1 antibodies reported above. Interestingly, it 
was found that intravitreous administration of WIG sup-
pressed choroidal neovascularization in wild-type mice as 
effectively as intravenous administration of WIG (FIG. 30). 
of neovascular AMD that is driven in large part by Vegfa and 
was predictive of the success of anti-VEGFA therapies in 
humans. Various drugs were administered by intravitreous 
injection immediately after surgery. By day 7, it was found 
that bevacizumab or human IgG 1 but not ranibizumab 
inhibited choroidal neovascularization in wild-type mice 
compared to PBS administration (FIGS. 9 and 10). How-
ever, neither bevacizumab nor human IgG 1 inhibited char- 65 
oidal neovascularization in Fcgr1-1- mice (FIG. 11). A 
peptide that blocks IgG binding to FcyRI (ref.20), but not a 
60 These data open the possibility of intraocular administration 
of IVIG as an anti-angiogenic therapy. 
Example 6: mAbs Reduce Angiogenesis in FcyR 
Humanized Mice 
Although human IgGl binds and activates mouse FcyRI 
similarly as it does human Fey RI, the structural diversity and 
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unique cellular expression patterns of mouse and human 
FcyRs are not synonymous25 . The generation of an FcyR 
humanized mouse via transgenic expression of the entire 
human FcyR family, under the control of their human 
regulatory elements, on a genetic background lacking all 5 
mouse FcyRs has enabled better prediction of the functional 
consequences of engaging human Fey Rs by IgGs (ref.26). In 
these FcyR humanized mice, it was found that bevacizumab 
reduced corneal and choroidal neovascularization just as in 
wild-type mice (FIGS. 31 and 32). These data further 10 
increase the likelihood that similar, target-independent 
angioinhibitory activity of humanized monoclonal IgG 1 
antibodies or WIG could be observed in humans. 
14 
previously. CNV volumes per laser lesion were compared by 
hierarchical logistic regression using repeated measures 
analysis. 
Cornea Suture Placement. 
In anesthetized animals, two interrupted 11-0 nylon 
sutures (Mani, Inc., Utsunomiya, Japan) were placed into the 
corneal stroma, midway between the central corneal apex 
and the limbus (approximately 1.25 mm from the limbus), of 
both eyes of mice. Delivery of antibodies (100 µg) or PBS 
was performed into corneal stroma on day O (immediately 
after suture placement), day 4, and day 8 following injection. 
Injections were performed using a 33-gauge Exmire 
Microsyringe (Ito Corporation) Animals were sacrificed at 
Example 7: IgGl mAbs Reduce Angiogenesis Via 
c-cbl in Macrophages 
15 
day 10, the eyes were enucleated, and the corneas were 
dissected for further analyses. 
Corneal Flat Mounts. 
After euthanasia, the corneas were isolated, washed in 
PBS, and fixed in 4% paraformaldehyde for 1 hour and 
20 acetone for 20 minutes at room temperature. Corneas were 
washed in 0.1 % Tween-20 in PBS and blocked in 3% BSA 
To determine whether circulating or resident cell types 
were the critical effectors in IgGl mAb-mediated angioin-
hibition, bone marrow chimeric mice were created. Beva-
cizumab suppressed angiogenesis in the cornea and the 
choroid in Fcgrl -/- mice receiving wild-type bone marrow 
but did not do so in wild-type mice receiving Fcgrl -I- bone 
marrow (FIG. 33-35). These results indicate that FcyRI 
expression in circulating bone marrow-derived cells is criti- 25 
cal for bevacizumab-induced angioinhibition. The effects of 
humanized IgG 1 mAbs on macrophages were studied 
because these circulating immune cells play a critical role in 
angiogenesis. Both bevacizumab and human IgG 1 inhibited 
mouse Vegfa-induced migration of wild-type mouse bone 30 
marrow derived macrophages (BMDMs) but not ofFcgr1-1-
in PBS for 48 hours. Incubation with rabbit anti-mouse 
LYVE-1 antibody (1:333; Abeam) and rat anti-mouse CD31 
antibody (1:50; BD Biosciences, San Jose, Calif.) was 
performed for 48 hours at 4 ° C. The corneas were washed in 
0.1 % Tween-20 in PBS and incubated for 2 hours with Alexa 
Fluor 488 (goat anti-rabbit; 1:200; Invitrogen) and Alexa 
Flour 594 (goat anti-rat; 1:200; Invitrogen). Corneal flat 
mounts were visualized under fluorescent microscopy 
(Olympus, Tokyo, Japan). The images were adjusted for 
brightness/contrast, and converted to black and white 
or c-cbr-1- BMDMs (FIG. 36-38). 
Bevacizumab induced phosphorylation of c-cbl (FIG. 39), 
a kinase that is activated by IgGl binding to FcyRI, in 
wild-type mouse bone marrow derived macrophages. Beva- 35 
cizumab did not inhibit corneal neovascularization in 
c-cbr-1- mice (FIG. 40), indicating that c-cbl activation is 
essential in this process. 
images. Next, whole corneas were outlined using ImageJ 
software (NIH). Contours of lymphatic or bloodstained 
vessels inside the previously outlined area were optimized 
by threshold and converted to binary images. Area fraction 
(%) of neovascularized cornea was calculated compared to 
whole corneal surface. 
Peptide Synthesis. 
Example 8: Methods 
Animals. 
All animal experiments were in accordance with the 
guidelines of the University of Kentucky Institutional Ani-
mal Care and Use Committee, and the Association for 
Research in Vision and Ophthalmology (ARVO) Animal 
Statement for the Use of Animals in Ophthalmic and Vision 
Research. C57B16/J mice were purchased from The Jackson 
Laboratory (Bar Harbor, Me.). For all procedures, anesthesia 
was performed by intraperitoneal injection of 100 mg/kg 
ketamine hydrochloride (Ft. Dodge Animal Health, Ft. 
Dodge, Iowa) and 10 mg/kg xylazine (Phoenix Scientific, St. 
Joseph, Mo.). Pupils were dilated with topical tropicamide 
(1 %; Alcon Laboratories, Inc., Fort Worth, Tex.). 
Choroidal N eovascularization. 
Subretinal injections of antibodies (25 µg in 1 µL) in mice 
were performed using a Pico-Injector (PLI-100; Harvard 
Apparatus, Holliston, Mass.). CNV had been induced by 
laser photocoagulation (532 nm, 200 mW, 100 ms, 75 µm; 
OcuLight GL; IRIDEX Corporation, Mountain View, Calif.) 
performed on both eyes ( 4 spots per eye for volumetric 
analyses) of each 6- to 8-week-old male mice (N=4 per 
group). Seven days later CNV volumes were measured by 
staining with 0.5% FITC-conjugated Griffonia simplicifolia 
Isolectin B4 (Vector Laboratories, Burlingame, Calif.). 
RPE-choroidal flat mounts using scanning laser confocal 
microscope (TCS SP; Leica, Wetzlar, Germany), as reported 
40 The tetrameric tripeptide PAM (D-Arg-D-Thr-D-Tyr )4 -L-
Lys2-L-Lys-Gly, and the scrambled control peptide (D-Thr-
D-Tyr-D-Arg)4-L-Lys2-L-Lys-Gly, (MW 2144), were pro-
duced by solid-phase peptide synthesis by using amino acids 
in the D configuration. Purified peptides were dissolved at 
45 the working concentration in PBS. 
Hindlimb Ischemia. 
C57Bl/6J mice (N=7 per group) were anesthetized before 
underwent unilateral proximal femoral artery ligation. The 
right femoral artery was gently isolated, ligated and excised 
50 distal to the deep femoral artery and 0.5 cm proximal to the 
bifurcation in saphenous and popliteal arteries, as previously 
described (3). The non-ischemic left limb underwent a sham 
surgery without arterial ligation Immediately following sur-
gery and after 48 h, Avastin (375 µg), Lucentis (300 µg), 
55 Human IgG (375 µg), PAM peptide (1 mg), Avastin plus 
PAM or Avastin plus Control Peptide (1 mg) were intra-
muscularly administered in a total volume of 30 µL to each 
hindlimb. The same volume of PBS was injected in control 
group. To evaluate the activity of commercial human intra-
60 venous immunoglobulin (IVIG), 0.5 ml (2 g/kg) of IVIG 
(Baxter) or PBS were delivered intravenously by tail vein 
injection immediately after surgery and after 72 h. 7 days 
later, both anterior and posterior muscles from ischemic and 
non-ischemic hindlimbs were harvested and processed for 
65 immunohistochemical analysis to quantify angiogenesis and 
lymphangiogenesis. In order to evaluate monocyte-macro-
phage infiltrate, C57Bl/6J mice underwent artery ligation 
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were resolved by SDS-PAGE on Novex® Tris-Glycine Gels 
(Invitrogen), and transferred onto Immun-Blot PVDF mem-
branes (Bio-Rad). The transferred membranes were blocked 
for 1 hr at RT and incubated with antibodies against phos-
pho-VEGFR2 (1: 1000; Cell Signaling) or phospho-c-Cbl 
(1: 1000; Cell Signaling), at 4'C overnight. The immunore-
active bands were developed by enhanced chemilumines-
cence reaction. Protein loading was assessed by western 
blotting using an anti-Tubulin antibody (1:1000; Sigma-
Aldrich). 
Avastin Deglycosylation. 
To deglycosylate Avastin, it was treated with PNGaseF 
(New England BioLab, Beverly, Mass.). Briefly, the Avastin 
For mouse tissues, capillaries were stained with anti- 5 
CD31 (BD Biosciences) or anti-LYVE-1 antibodies (Ab-
eam), monocyte-macrophages with anti-F4/80 (Serotec), 
and then with biotin labeled Goat anti rat secondary anti-
bodies (Dako ). For human tissues, capillaries were stained 
with anti-CD-31 (Dako) or anti-LYVE-1 antibodies (Ab- 10 
cam) and then with biotin labeled goat anti mouse secondary 
antibodies (Dako ). Five optical fields for each sample were 
analyzed. Capillary number was normalized to myocyte 
number. Ischemic/non-ischemic ratio of vessel density or 
F4/80 positive area was calculated. 15 were first denatured at 100° C. for 10 min in glycoprotein 
denaturing buffer and then chilled on ice. Following addition 
of G7 reaction buffer, the deglycosylation enzyme cocktail 
was added and incubated reaction at 37° C. for 4 hours. 
Color Laser Doppler Analysis. 
Color laser doppler analysis were performed 2 and 7 days 
after femoral artery ligation using a dedicated Laser Doppler 
Perfusion Imaging System (LDPI, Petimed AB) with high 
resolution, in single mode. Hindlimbs were depilated and 20 
mice were placed on a heating plate at 37° C. The distance 
between the seamier head and tissue surface was 8 cm. An 
area of 5x5 cm was sequentially scamied and blood flow 1 
mm under the surface was measured. Color-coded images 
were recorded, and analyses were performed calculating the 25 
average perfusion of the right and left distal limb. Dark blue 
color implied low or absent perfusion whereas red implied 
maximal perfusion. 
Macrophage Migration Assay. 
2xl04 BMDM cells were isolated from mice and sus- 30 
pended in 2% BMDM medium and seeded onto the upper 
chamber of the 8 µM polycarbonate filter (12-transwell 
format. The antibodies namely Avastin or IgG at concentra-
tion of 0.1 mg/ml or recombinant mouse Vegfa (50 ng/ml) 
were placed in the lower chamber. After 4 h of incubation the 35 
lower chambers with Avastin and IgG were respectively 
replaced with Avastin+mouse Vegfa and IgG+mouse Vegfa 
and incubated for 12 h. Macrophages that had not migrated 
and remained in the upper chamber were removed by gently 
washing the upper chamber with PBS and fixed with 4% 40 
buffered paraformaldehyde for 15 min and permeabilized 
with 0.025% triton-Xl00 for 10 min followed by staining 
with Hoescht (1: 1000) for 30 min. The membrane inserts 
were washed and filers inserts were mounted using 
Vectashield fluorescence mounting medium. BMDM cells 45 
found on the filter, in the lower chamber, were counted as 
cells having undergone chemotaxis and quantified by fluo-
rescence for cell number. Macrophages were quantified for 
total number of cells migrated from the entire 32 mm 
diameter membrane (20x magnification of montage images) 50 
acquired using Cell Dimension Software. Cell numbers were 
acquired using NIH-Image J and the experiment for each 
condition was performed in triplicate. 
Receptor Phosphorylation and Western Blotting. 
Py4 mouse blood endothelial cells were starved for 16 55 
hours in absence of FBS. To induce VEGFR-2 activation, 
cells were stimulated with 50 ng/ml of mVegf-A or 
hVEGF-A for 10 minutes. 0.1 mg/ml Avastin (Genentech) 
was added to medium at the same time. As a control, 0.75 
µg/ml neutralizing anti-mouse Vegf-AmAb (R&D Systems) 60 
was used. To activate c-cbl phosphorylation, 1774 mouse 
macrophages were starved for 4 h in absence of FBS and 
then stimulated with 0.1 mg/ml of Avastin (Genentech) or 
human IgG (Sigma-Aldrich) for 45 min. Cells lysed in RIPA 
lysis buffer (Sigma-Aldrich) supplemented protease cocktail 65 
inhibitor were homogenized by sonication. Equal amounts 
of protein samples (20-40n) prepared in Laemmli buffer 
Either mock-treated or deglycosylated Avastin were sub-
jected to SDS-PAGE and Coomassie to appreciate the 
mobility shift following the glycosylation procedure. 
Avastin Fab/Fc Fragmentation. 
Avastin Fe and Fab fragments were prepared by using a 
ImmunoPure Fab Preparation Kit (Thermo Fisher Scientific) 
according to the manufacturer's instructions. In brief, 4 mg 
of Avastin was mixed with 0.5 ml of immobilized papain. 
The mixture was incubated by shaking overnight at 37° C. 
Crude digest was separated from immobilized papain and 
applied to a protein A colunm (Affinity Pak; Thermo Fisher 
Scientific). Fab fragments were recovered in the flow 
through. Fe fragments and undigested IgG bound to the 
colunm were eluted with elution buffer. The fragmentation 
was confirmed in a reducing 4-12% NuPAGE gels stained 
with SimplyB!ue SafeStain (Invitrogen Corp.). The more 
clear Fab and Fe fraction were chosen and concentrated 
using a Vivaspin 20 centrifugal concentrator (10-kDa 
molecular weight cutoff; Sartorius Stedim Biotech). 
Statistical Analysis. 
Data are expressed as mean±SEM, with P<0.05 consid-
ered statistically significant. Differences among groups were 
tested by one-way ANOVA. Tukey HD test was used as a 
post hoc test to identify which group differences account for 
the significant overall ANOV A. All calculations were carried 
out using SPSS statistical package (vers 12.1; SPSS, Inc., 
Chicago, Ill.). 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by ref-
erence, including the references set forth in the following 
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